FG001 (FGS)

About FluoGuide

FluoGuide is a Danish biotech company pioneering precision surgery through its uPAR-targeting fluorescent imaging agent, FG001. The company has successfully completed Phase II trials in aggressive brain cancer (high-grade glioma) and head & neck cancer, demonstrating clinical proof-of-concept. FluoGuide is advancing its pipeline towards Phase III and exploring therapeutic applications of its technology via photothermal treatment. The company is publicly listed on Nasdaq First North Growth Market and has secured strategic partnerships with industry leaders like Intuitive Surgical.

About FluoGuide

FluoGuide is a Danish biotech company pioneering precision surgery through its uPAR-targeting fluorescent imaging agent, FG001. The company has successfully completed Phase II trials in aggressive brain cancer (high-grade glioma) and head & neck cancer, demonstrating clinical proof-of-concept. FluoGuide is advancing its pipeline towards Phase III and exploring therapeutic applications of its technology via photothermal treatment. The company is publicly listed on Nasdaq First North Growth Market and has secured strategic partnerships with industry leaders like Intuitive Surgical.

Therapeutic Areas